Wolf Haldenstein Adler Freeman & Herz LLP is investigating possible securities fraud by Curanex Pharmaceuticals and its executives following extreme stock price volatility after its IPO in August 2025. The stock price surged to $9.16 before plummeting to $1.51 amid heavy trading volume, leading to a trading halt. Shareholders who suffered losses may have claims, and the law firm invites them to contact for potential legal action. This probe could impact investor confidence and the company's future market activity.
The S&P 500 fell 0.07% to 7,403.05 on Monday, marking its second consecutive decline, pressured by weakness in AI-related technology stocks after Seagate warned of supply constraints. Despite this, Wall Street remains near record highs following a st...
The global nebulizer market, valued at $1.5 billion in 2025, is projected to reach $2.2 billion by 2032, growing at a 5.9% CAGR. Growth is fueled by technological innovations like portable mesh nebulizers, increasing respiratory disease prevalence, a...
ROCKWOOL A/S reported a 2% revenue increase in Q1 2026, reaching 906 million euros despite geopolitical tensions and weather issues. EBITDA was 187 million euros with a 20.7% margin, slightly down due to production disruptions and weak markets in Can...
The global makeup remover market is projected to grow from $1.6 billion in 2025 to $2.1 billion by 2032, at a CAGR of 4%. Growth is fueled by innovations such as AI-driven product recommendations, sustainable packaging, and microbiome-friendly formul...
In the first quarter of 2026, hedge funds dramatically increased their investments in semiconductor stocks, pushing sector exposure to a record 19% of global hedge fund portfolios, more than doubling since the start of the year. Major investors like ...
